[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR0011127A - Derivados de 4-fenil-pirimidina - Google Patents

Derivados de 4-fenil-pirimidina

Info

Publication number
BR0011127A
BR0011127A BR0011127-9A BR0011127A BR0011127A BR 0011127 A BR0011127 A BR 0011127A BR 0011127 A BR0011127 A BR 0011127A BR 0011127 A BR0011127 A BR 0011127A
Authority
BR
Brazil
Prior art keywords
lower alkyl
hydrogen
phenyl
halogen
pyrimidine derivatives
Prior art date
Application number
BR0011127-9A
Other languages
English (en)
Inventor
Michael Boes
Guido Galley
Thierry Godel
Torsten Hoffmann
Walter Hunkeler
Patrick Schnider
Heinz Stadler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR0011127A publication Critical patent/BR0011127A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Patente de Invenção: "DERIVADOS DE 4-FENIL-PIRIMIDINA". A invenção refere-se a compostos de fórmula (I) onde R^ 1^ é hidrogênio ou halogênio; R^ 2^ é hidrogênio, halogênio, alquila inferior ou alcóxi inferior; R^ 1^ e R^ 2^ podem ser juntos com os dois átomos de carbono -CH=CH-CH=CH-; R^ 3^ é halogênio, trifluorometila, alquila inferior ou alcóxi inferior; R^ 4^ R^ 4^' são independentemente um do outro hidrogênio ou alquila inferior; R^ 5^ é alquila inferior, alcóxi inferior, amino, fenila, alquila inferior de hidróxi, alquila inferior de ciano, alquila inferior de carbamoíla, piridila, pirimidila, -(CH~ 2~)~ n~-Piperazinila, que é opcionalmente substituída por um ou dois grupos de alquila inferior ou por alquila inferior de hidróxi, -(CH~ 2~),-morfolinila, -(CH~ 2~)~ n~-Piperidinila, -(CH~ 2~)~ n+1~-imidazolila, sulfanila de alquila inferior, sulfonila de alquila inferior, benzilamino, -NH-(CH~ 2~)~ n+1~R(R^ 4^")~ 2~, -(CH~ 2~)~ n+1~N(R^ 4^")~ 2~, -O(CH~ 2~)~ n+1~-morfolinila, -O-(CH~ 2~)~ n+1~"-piperidinila ou -O-(CH~ 2~)~ n+1~N(R^ 4^")~ 2~, onde R^ 4^" é hidrogênio ou alquila inferior; e n é 0 a 2; X é -C(O)N(R^ 4^")- ou -N(R^ 4^)C(O)-; e a sais de adição de ácido farmaceuticamente aceitáveis destes. Foi demonstrado que os compostos têm uma boa afinidade ao receptor de NK-1 e pode portanto ser empregado para o tratamento de doenças relacionadas a este receptor.
BR0011127-9A 1999-05-31 2000-05-24 Derivados de 4-fenil-pirimidina BR0011127A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99110483 1999-05-31
PCT/EP2000/004701 WO2000073279A1 (en) 1999-05-31 2000-05-24 4-phenyl-pyrimidine derivatives

Publications (1)

Publication Number Publication Date
BR0011127A true BR0011127A (pt) 2002-02-19

Family

ID=8238271

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0011127-9A BR0011127A (pt) 1999-05-31 2000-05-24 Derivados de 4-fenil-pirimidina

Country Status (36)

Country Link
US (1) US6274588B1 (pt)
EP (1) EP1187815B1 (pt)
JP (1) JP3590592B2 (pt)
KR (1) KR100440106B1 (pt)
CN (1) CN1166643C (pt)
AR (1) AR024146A1 (pt)
AT (1) ATE317389T1 (pt)
AU (1) AU770786B2 (pt)
BR (1) BR0011127A (pt)
CA (1) CA2375671C (pt)
CO (1) CO5170520A1 (pt)
CZ (1) CZ20014271A3 (pt)
DE (1) DE60025918T2 (pt)
DK (1) DK1187815T3 (pt)
ES (1) ES2257294T3 (pt)
GC (1) GC0000191A (pt)
HK (1) HK1046528B (pt)
HR (1) HRP20010871A2 (pt)
HU (1) HUP0201315A3 (pt)
IL (2) IL146460A0 (pt)
JO (1) JO2261B1 (pt)
MA (1) MA26793A1 (pt)
MX (1) MXPA01012089A (pt)
MY (1) MY122731A (pt)
NO (1) NO321354B1 (pt)
NZ (1) NZ515407A (pt)
PE (1) PE20010153A1 (pt)
PL (1) PL353441A1 (pt)
PT (1) PT1187815E (pt)
RU (1) RU2243221C2 (pt)
SI (1) SI1187815T1 (pt)
TR (1) TR200103457T2 (pt)
TW (1) TW550258B (pt)
WO (1) WO2000073279A1 (pt)
YU (1) YU84901A (pt)
ZA (1) ZA200109163B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ514600A0 (en) 2000-01-18 2000-02-10 James Cook University Brain injury treatment
AU2001284504A1 (en) * 2000-09-14 2002-03-26 Ajinomoto Co., Inc. Novel pyrimidine derivative and novel pyridine derivative
CZ20032233A3 (cs) * 2001-02-20 2004-12-15 Bristol-Myers Squibb Company Derivát 2,4-disubstituovaného pyrimidin-5-karboxamidu jako modulátor draslíkového kanálku KCNQ
EP1679309A4 (en) * 2003-10-24 2007-03-28 Ono Pharmaceutical Co ANTISTRESS MEDICAMENT AND ITS MEDICAL USE
HUP0400405A3 (en) * 2004-02-10 2009-03-30 Sanofi Synthelabo Pyrimidine derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates
US7767680B2 (en) 2004-11-03 2010-08-03 Vertex Pharmaceuticals Incorporated Ion channel modulators and methods of use
US7176205B2 (en) * 2005-02-22 2007-02-13 Hoffmann-La Roche Inc. Bi-pyridinyl derivatives as NK-1 antagonists
JP2008531509A (ja) 2005-02-25 2008-08-14 エフ．ホフマン−ラ ロシュ アーゲー 医薬品成分の改良された分散性を有する錠剤
JP5118029B2 (ja) * 2005-06-14 2013-01-16 タイゲン バイオテクノロジー カンパニー，リミテッド ピリミジン化合物
EP2268635B1 (en) 2008-04-21 2015-06-10 Taigen Biotechnology Co., Ltd. Heterocyclic compounds
US8580805B2 (en) * 2010-08-31 2013-11-12 Hubert Maehr Pyrimidine carboxamide derivatives
KR20170107536A (ko) * 2015-01-30 2017-09-25 바스프 에스이 제초 페닐피리미딘
KR102335082B1 (ko) * 2017-01-10 2021-12-06 내셔날 헬스 리서치 인스티튜트 헤테로사이클릭 화합물 및 이의 용도
KR102006547B1 (ko) * 2017-11-16 2019-08-01 서울대학교산학협력단 벤즈아미드 유도체 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 염증질환의 치료 또는 예방용 약학적 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4698340A (en) 1984-07-19 1987-10-06 Fujisawa Pharmaceutical Co., Ltd. Pyrimidine derivatives, processes for preparation thereof and composition containing the same
DE3614060A1 (de) * 1986-04-23 1987-10-29 Schering Ag Pyrimidin-derivate, verfahren zu ihrer herstellung und ihre verwendung als fungizide
US5516775A (en) * 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
PL181214B1 (pl) 1993-12-29 2001-06-29 Merck Sharp & Dohme Podstawione związki morfolinowe, sposób ich wytwarzania oraz zawierające je kompozycje farmaceutyczne
CA2230894A1 (en) 1995-09-01 1997-03-13 Signal Pharmaceuticals, Inc. Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions
US5972938A (en) 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders

Also Published As

Publication number Publication date
NO20015700D0 (no) 2001-11-22
DK1187815T3 (da) 2006-06-19
CN1353697A (zh) 2002-06-12
HUP0201315A3 (en) 2003-02-28
CO5170520A1 (es) 2002-06-27
ES2257294T3 (es) 2006-08-01
HRP20010871A2 (en) 2003-04-30
MA26793A1 (fr) 2004-12-20
HUP0201315A2 (hu) 2002-12-28
WO2000073279A1 (en) 2000-12-07
EP1187815B1 (en) 2006-02-08
SI1187815T1 (sl) 2006-06-30
NZ515407A (en) 2004-03-26
IL146460A (en) 2006-10-31
NO20015700L (no) 2001-11-22
HK1046528B (zh) 2005-02-25
MY122731A (en) 2006-04-29
ATE317389T1 (de) 2006-02-15
MXPA01012089A (es) 2002-06-04
AU4567700A (en) 2000-12-18
IL146460A0 (en) 2002-07-25
JP2003500478A (ja) 2003-01-07
AU770786B2 (en) 2004-03-04
PT1187815E (pt) 2006-06-30
HK1046528A1 (en) 2003-01-17
AR024146A1 (es) 2002-09-04
TW550258B (en) 2003-09-01
EP1187815A1 (en) 2002-03-20
PE20010153A1 (es) 2001-02-08
DE60025918T2 (de) 2006-09-28
PL353441A1 (en) 2003-11-17
KR100440106B1 (ko) 2004-07-14
CA2375671A1 (en) 2000-12-07
CA2375671C (en) 2009-08-25
JO2261B1 (en) 2004-10-07
NO321354B1 (no) 2006-05-02
ZA200109163B (en) 2003-02-06
CZ20014271A3 (cs) 2002-05-15
RU2243221C2 (ru) 2004-12-27
GC0000191A (en) 2006-03-29
KR20020000826A (ko) 2002-01-05
JP3590592B2 (ja) 2004-11-17
TR200103457T2 (tr) 2002-04-22
DE60025918D1 (de) 2006-04-20
CN1166643C (zh) 2004-09-15
US6274588B1 (en) 2001-08-14
YU84901A (sh) 2004-09-03

Similar Documents

Publication Publication Date Title
BR0011127A (pt) Derivados de 4-fenil-pirimidina
BR0011097A (pt) Derivados de 5-fenil-piridina
ES2171109A1 (es) Derivados de 4-fenil-piridina.
BR0008489A (pt) Derivados de fenil- e piridinila
BR0112475A (pt) N-óxidos como pró-drogas antagonistas de receptor de nk1 de derivados 4-fenil-piridina
YU8703A (sh) Derivati 4-fenil-piridina kao antagonisti receptora neurokinina-1
HUP0204226A2 (en) Quinazoline derivatives, pharmaceutical compositions containing them, their use and process for the preparation of the compounds
BRPI0519794A2 (pt) derivados de [4-(heteroaril)piperazin-1-il]-(fenil 2,5-substituìdo)metanona como inibidores de transportador de glicina 1 (glyt-1) para o tratamento de distúrbios neurológicos e neuropsiquiátricos
AU4483000A (en) Inhibitors of c-jun n-terminal kinases (jnk)
BR0313846A (pt) Derivados de dioxano-2-alquilcarbamatos, sua preparação e sua aplicação em terapêutica
ATE327225T1 (de) Neue verwendung von benzothiazolderivaten
AR006360A1 (es) Derivados de 1,2,3,4-tetrahidronaftaleno substituidos, uso de los mismos para la preparacion de medicamentos y procedimiento para su preparacion.
MXPA06001094A (es) Compuestos quimicos.
BRPI0518615A2 (pt) derivados de malonamida
YU64901A (sh) Derivati bifenila
BR0205683A (pt) Processo para a preparação de derivados de piperazina, e, mesilato de um composto
BR0115480A (pt) Derivados de pirimidina
BR0214488A (pt) Derivados de benzotiazol
DK1178047T3 (da) Diazabicyclooctanderivater og terapeutiske anvendelser deraf
DK0470686T3 (da) (Benzhydryloxyethylpiperidyl)alifatiske syrederivater og deres anvendelse til behandling af allergier og astma
WO2009019721A3 (en) Quercetin derivatives as anti-cancer agents
BR0212839A (pt) Derivados de alquilaminopiridazinona substituìdos, processo para a preparação destes e composição farmacêutica contendo os mesmos
DK1083178T3 (da) Tetrahydroquinazolin-2,4-dioner og terapeutiske anvendelser deraf
NO20033049D0 (no) Fremgangsmåte for fremstilling av (+/-) trans-4-p-fluorfenyl- 3-hydroksymetyl-1
AU694513B2 (en) Cyclobut-3-ene-1,2-dione derivatives as smooth muscle relaxants

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL: C07D 239/28, C07D 239/42, C07D 239/34, C07D 239/48, C07D 239/38, C07D 401/04, A61K 31/505, A61P 29/00

Ipc: C07D 239/28 (2009.01), C07D 239/42 (2009.01), C07D

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 11, 13 E 25 DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.